Unicycive Therapeutics rises on FDA's 'orphan' tag for kidney failure drug

Unicycive Therapeutics

04/03/2024 12:31

** Shares of Unicycive Therapeutics  UNCY.O  rise ~1.9% to
$1.63 premarket
    ** Co says the U.S. FDA has granted an "orphan" designation
to its drug UNI-494 for the prevention of delayed graft function
(DGF) 
    ** DGF is a form of kidney failure and a common complication
experienced by kidney transplant recipients
    ** Orphan drug status is given by the FDA to drugs that
treat rare conditions and are protected through a series of
government incentives once in market
    ** Up to last close, stock more than tripled in the last 12
months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))